Shield Therapeutics Plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Karl Anders Lundström
- Full Time Employees
- 61
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Northern Design Centre Gateshead Quays GH United Kingdom NE8 3DF
- IPO Date
- Feb 26, 2016
- Website
- shieldtherapeutics.com
- Similar Companies
- Business
- Shield Therapeutics plc (LSE:STX) is a UK-based commercial-stage specialty pharmaceutical company focused on developing and commercializing treatments for iron deficiency with or without anemia. The company offers ACCRUFeR®/Feraccru® (ferric maltol), a novel, stable, non-salt-based oral iron therapy indicated for adults across multiple therapeutic categories including inflammatory bowel disease, renal disease, and general iron deficiency; it is approved in the United States, European Union, United Kingdom, Canada, Australia, and Switzerland. Operations span North America, Europe, and Asia-Pacific through partnerships, with headquarters in Gateshead Quays, England; founded in 2008, subsidiaries include Shield Therapeutics Inc (US), Shield TX (Switzerland) AG, Shield TX (UK) Limited, and Phosphate Therapeutics Limited. Recent developments include an 80% revenue increase to $21.4 million in the first half of 2025 driven by ACCRUFeR® growth, particularly as the top branded prescription oral iron in the US; a £1.5 million placing in September 2025 via 20 million new shares to support US expansion and working capital; and a $5.7 million cash receipt from AOP Health in exchange for China milestone rights. Strategic alliances encompass exclusive licenses with Viatris for US co-commercialization, Kye Pharmaceuticals for Canada (launched March 2025), VITAL-NET for Japan (April 2025, $665,000 upfront), Beijing Aosaikang Pharmaceutical for China/Hong Kong/Macau/Taiwan (Phase 3 completed for IBD patients, NDA filing pending), and Korea Pharma for South Korea. These partnerships and financings bolster global commercialization amid progress toward cash flow positivity by end-2025.
Company News
Shield Therapeutics plc (SHIEF) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR Transcript
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Shield Therapeutics jumps 11% as losses narrow and profitability target held
Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript
Shield Therapeutics shares slip after interims, small-cap pharma says its still 'on-track'
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
Shield shares jump after FDA extends Accrufer exclusivity
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
Shield Therapeutics shares positive efficacy data for iron deficiency treatment
Shield Therapeutics lifted as US FDA extends Accufer approval
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double
Shield Therapeutics rises on Japan licensing deal for iron deficiency drug
Shield Therapeutics edges closer to profitability as US sales surge
Shield Therapeutics shares rise on the back of $10m fundraiser
Shield Therapeutics unveils premium fundraiser
Shield Therapeutics ‘on track for 2024' - analyst
Shield Therapeutics up 27% after impromptu trading update
Shield Therapeutics on course in China as sales growth continues